Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 11/20 | 0.76 |
| ▸ | MMP2 | P08253 | 10/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.53 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.53 |
| ▸ | MMP13 | P45452 | 3/20 | 0.52 |
| ▸ | MMP3 | P08254 | 2/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | HPN | P05981 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP7 | P09237 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL457772 | 1.00 | MMP9 (0.76) | MMP9MMP2TDP1ITGB3ITGA2B | |
| SCHEMBL10585071 | 1.00 | MMP9 (0.76) | MMP9MMP2TDP1ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL9087107 | 0.99 | MMP9 (0.74) | MMP9MMP2TDP1ITGB3ITGA2B | |
| SCHEMBL8322406 | 0.96 | MMP9 (0.71) | MMP9MMP2TDP1ITGB3ITGA2B | |
| SCHEMBL158952 | 0.96 | MMP9 (0.70) | MMP9MMP2TDP1ITGB3ITGA2B | |
| SCHEMBL158951 | 0.96 | MMP9 (0.70) | MMP9MMP2TDP1ITGB3ITGA2B | |
| SCHEMBL232590 | 0.95 | MMP9 (0.70) | MMP9MMP2TDP1ITGB3ITGA2B | |
| SCHEMBL796113 | 0.95 | MMP9 (0.70) | MMP9MMP2TDP1ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL14059216 | 0.94 | MMP9 (0.68) | MMP9MMP2TDP1ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL28895937 | 0.94 | MMP9 (0.68) | MMP9MMP2TDP1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388669-A1 | MULTI-SPECIFIC ANTIBODIES IN USES THEREOF IN AVIDITY RECEPTOR CROSSLINKING AND IMMUNE MODULATION | Wang, Jieyi (US) | 2025-12-25 | — | — | US | disclosed |
| EP-3240570-B1 | BISPECIFIC ANTIBODIES AGAINST PLASMA KALLIKREIN AND FACTOR XII | TAKEDA PHARMACEUTICALS CO (JP) | 2025-09-24 | — | — | EP | disclosed |
| US-20250263504-A1 | BISPECIFIC ANTIBODIES AGAINST PLASMA KALLIKREIN AND FACTOR XII | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-08-21 | — | — | US | disclosed |
| US-12240918-B2 | Bispecific antibodies against plasma kallikrein and factor XII | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-03-04 | — | — | US | disclosed |
| WO-2025024646-A1 | MULTI-SPECIFIC ANTIBODIES INTEGRATING DUAL IMMUNE MODULATING MOIETIES AND USES THEREOF IN IMMUNOTHERAPY | LYVGEN BIOPHARMA HOLDINGS LIMITED (KY) | 2025-01-30 | — | — | WO | disclosed |
| EP-4466020-A2 | MULTI-SPECIFIC ANTIBODIES IN USES THEREOF IN AVIDITY RECEPTOR CROSSLINKING AND IMMUNE MODULATION | Lyvgen Biopharma Holdings Limited (KY) | 2024-11-27 | — | — | EP | disclosed |
| US-20240218069-A1 | BI-SPECIFIC ANTIBODIES COMPRISING ANTI-B7H3 BINDING MOLECULES | LYVGEN BIOPHARMA HOLDINGS LIMITED (KY) | 2024-07-04 | — | — | US | disclosed |
| US-20230406950-A1 | BI-SPECIFIC ANTIBODIES COMPRISING ANTI-CD137 BINDING MOLECULES | LYVGEN BIOPHARMA HOLDINGS LIMITED (KY) | 2023-12-21 | — | — | US | disclosed |
| WO-2023141611-A2 | MULTI-SPECIFIC ANTIBODIES IN USES THEREOF IN AVIDITY RECEPTOR CROSSLINKING AND IMMUNE MODULATION | LYVGEN BIOPHARMA HOLDINGS LIMITED (KY) | 2023-07-27 | — | — | WO | disclosed |
| US-20230117565-A1 | BISPECIFIC ANTIBODIES AGAINST PLASMA KALLIKREIN AND FACTOR XII | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-04-20 | — | — | US | disclosed |
| CN-114044898-B | Lysine grafted polyethyleneimine cationic gene vector and preparation method and application thereof | 中国科学院长春应用化学研究所 | 2022-07-12 | — | — | CN | disclosed |
| CN-114044898-A | Lysine grafted polyethyleneimine cationic gene vector and preparation method and application thereof | 中国科学院长春应用化学研究所 | 2022-02-15 | — | — | CN | disclosed |
| WO-2019208721-A1 | HAIR MOISTURIZER, WHITENING AGENT, AND WHITENING COSMETIC | 株式会社成和化成 (JP) | 2019-10-31 | — | — | WO | disclosed |
| CN-104017787-B | The novel treatment molecule based on protein of one class | 安迅生物制药公司 | 2017-03-29 | — | — | CN | disclosed |
| CN-1328568-A | Peptide derivatives | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-12-26 | — | — | CN | disclosed |
| US-6127144-A | PRODUCING HETEROLOGOUS PROTEINS BY INCUBATING STREPTOMYCES CELL TRANSFORMED WITH NUCLEIC ACID EXPRESSION CONSTRUCT IN PRESENCE OF PEPTIDE-SUSBSTITUTED CHLOROMETHYLKETONE AMINOPEPTIDASE INHIBITOR HAVING DEFINED STRUCTURE | CANGENE CORPORATION (CA) | 2000-10-03 | — | — | US | disclosed |
| US-5856166-A | ENDOGENOUS TO STREPTOMYCES CELLS DEGRADES HETEROLOGOUS SECRETED FROM STREPTOMYCES HOST CELL | CANGENE CORPORATION (CA) | 1999-01-05 | — | — | US | disclosed |
| US-5616485-A | GENETIC ENGINEERING | CANGENE CORPORATION (CA) | 1997-04-01 | — | — | US | disclosed |
| EP-0731841-A1 | PROTEASES FROM STREPTOMYCES AND USE THEREOF IN PROTEIN EXPRESSION SYSTEMS | Cangene Corporation (CA) | 1996-09-18 | — | — | EP | disclosed |
| WO-1995017512-A2 | PROTEASES FROM STREPTOMYCES AND USE THEREOF IN PROTEIN EXPRESSION SYSTEMS | CANGENE CORPORATION (CA) | 1995-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388669-A1 | MULTI-SPECIFIC ANTIBODIES IN USES THEREOF IN AVIDITY RECEPTOR CROSSLINKING AND IMMUNE MODULATION | TNFRSF9, FCGR3B, FCGR2A | MMP9 3504/4885MMP2 3203/4885TDP1 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.